Prevalence of neutralizing factors against adeno-associated virus types 2 in age-related macular degeneration and polypoidal choroidal vasculopathy

Current Gene Therapy

Volumn 13, Issue 3, 2013, Pages 182-188

  Cheng, Yong ^a,b   Huang, Lvzhen ^a,b   Li, Xiaoxin ^a,b   Qi, Huijun ^a,b   Zhou, Peng ^a,b   Yu, Wenzhen ^a,b   Jiang, Yide A ^c   Wadsworth, Samuel ^c   Scaria, Abraham ^c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Peking University People s Hospital   (United States)

^c SANOFI   (France)

Author keywords

Adeno associated virus types 2; Age related macular degeneration; Neutralizing factors; Polypoidal choroidal vasculopathy

Indexed keywords

NEUTRALIZING ANTIBODY;

ADENO ASSOCIATED VIRUS; AGED; ARTICLE; BIOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RETINA MACULA AGE RELATED DEGENERATION; VIRUS NEUTRALIZATION;

AGED; CASE-CONTROL STUDIES; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PERIPHERAL VASCULAR DISEASES; SERUM; VITREOUS BODY;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2;

EID: 84878647879     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313030003     Document Type: Article

References (49)

1. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004/04/14 ed. 2004, p. 477-85.
2. Fine SL, Berger JW, Maguire MG and Ho AC. Age-related macular degeneration. N Engl J Med 2000; 342: 483-92.
3. Jager RD, Mieler WF and Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358: 2606-17.
4. Liu NP. Characteristics of age-related macular degeneration in Chinese population. Zhonghua Yan Ke Za Zhi 2009; 45: 393-5.
5. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of populationbased prevalence studies. Ophthalmic Epidemiol 2004; 11: 67-115.
6. Sayen A, Hubert I and Berrod JP. Age related macular degeneration. Rev Prat 2011; 61: 159-64.
7. Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ and Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol 2008; 52: 57- 62.
8. Maruko I, Iida T, Saito M, Nagayama D and Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144: 15-22.
9. Guyer DR, Yannuzzi LA, Slakter JS, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. Ophthalmology 1996; 103: 2054-60.
10. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158: 1161-72.
11. Spilsbury K, Garrett KL, Shen WY, Constable IJ and Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157: 135-44.
12. Abouammoh M, Sharma S. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011; 22: 152-8.
13. Chiang A, Regillo CD. Preferred therapies for neovascular agerelated macular degeneration. Curr Opin Ophthalmol 2011; 22: 199-204.
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA and Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72 e5.
15. Hara R, Kawaji T, Inomata Y, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol 2010; 248: 931-936.
16. Kim M, Kim K, Kim do G, Yu SY and Kwak HW. Two-year results of photodynamic therapy combined with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy. Ophthalmologica 2011; 226: 205-213.
17. Kokame GT, Yeung L and Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010; 94: 297-301.
18. Hauswirth WW and Beaufrere L. Ocular gene therapy: quo vadis? Invest Ophthalmol Vis Sci 2000; 41: 2821-2826.
19. Shen WY, Lai CM, Lai YK, et al. Practical considerations of recombinant adeno-associated virus-mediated gene transfer for treatment of retinal degenerations. J Gene Med 2003; 5: 576-587.
20. Ali RR, Reichel MB, De Alwis M, et al. Adeno-associated virus gene transfer to mouse retina. Hum Gene Ther 1998; 9: 81-86.
21. Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94: 6916-6921.
22. Rolling F, Shen WY, Tabarias H, et al. Evaluation of adenoassociated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Hum Gene Ther 1999; 10: 641-648.
23. Colella P and Auricchio A. AAV-mediated gene supply for treatment of degenerative and neovascular retinal diseases. Curr Gene Ther 2010; 10: 371-380.
24. Lorenz B, Preising M, Stieger K. Retinal blinding disorders and gene therapy--molecular and clinical aspects. Curr Gene Ther 2010; 10: 350-370.
25. Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009; 16: 10-6.
26. Lukason M, DuFresne E, Rubin H, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2011; 19: 260-265.
27. Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
28. Calcedo R, Vandenberghe LH, Gao G, Lin J and Wilson JM. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis 2009; 199: 381-390.
29. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704-712.
30. Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 2012; 19: 288-94.
31. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316-24.
32. Sanftner LM, Suzuki BM, Doroudchi MM, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 2004; 9: 403-9.
33. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-805.
34. Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008; 14: 1760-9.
35. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating antiwild- type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344-59.
36. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-74.
37. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314: 992-3.
38. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71: 1897-905.
39. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-67.
40. Berns KI. The Gordon Wilson Lecture. From basic virology to human gene therapy. Trans Am Clin Climatol Assoc 1999; 110: 75-85.
41. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
42. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier MC, Bessis N. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J Clin Immunol 2004; 24: 162-9.
43. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-11.
44. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003; 10: 964-76.
45. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adenoassociated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 2000; 74: 9281-93.
46. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001; 97: 3733-7.
47. Tobiasch E, Rabreau M, Geletneky K, et al. Detection of adenoassociated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol 1994; 44: 215-22.
48. Anand V, Chirmule N, Fersh M, Maguire AM, Bennett J. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther 2000; 11: 449-57.
49. Bennett J, Maguire AM, Cideciyan AV, et al. Stable transgene expression in rod photoreceptors after recombinant adenoassociated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A 1999; 96: 9920-5.